PLK1 and melanoma: Furthermore, our previous demonstration of PLK-1 as a potential therapeutic target in melanoma,41 together with the ability of PLK-1 inhibition to override MITF-mediated intrinsic resistance (Supplementary Figure S6) suggest mitotic kinases as potential avenues for therapeutic intervention in melanoma.